[Ip-health] Open letter from Latin-American civil society groups on the ‘MPP’ agreement with Gilead

Renata Reis renata at abiaids.org.br
Wed Jul 20 13:25:49 PDT 2011



Please find below a statement sing by more than 70 latin american organizations regarding the agreement singed by the MPP and Gilead. Attached to the message versions in Spanish and Portuguese.




Renata Reis 
Grupo de Trabalho sobre Propriedade Intelectual - GTPI/REBRIP

Associação Brasileira Interdisciplinar de AIDS - ABIA
Av. Presidente Vargas, 446/13 andar - Centro
Rio de Janeiro - RJ
tel +55 21 2223-1040  fax +55 21 2253-8495


Open letter from Latin-American civil society groups on the ‘MPP’ agreement with Gilead




The first license signed between the "Medicines Patent Pool" (MPP) and a pharmaceutical company frustrated the expectations of civil society groups in several countries. Launched as an innovative mechanism to promote access to patented medicines in developing and least developed countries, the MPP has contradicted the principles that justified it’s creation excluding several countries of the benefits of the first license announced, notably Latin American countries.

The agreement announced on July 12th, firmed with Gilead, allows the production by Indian companies of generic versions of the following HIV medicines: tenofovir, emtricitabine, and elvitegravir cobicistat and the combination of these four drugs in one pill known and Quad. It must be remembered that Gilead already had agreements with Indian companies since 2006 for the production of generic versions of the drugs Viread®  (tenofovir disoproxil fumarate or TDF) and Truvada® (tenofovir disoproxil fumarate + emtricitabine). These agreements allows Indian companies to sell only to certain countries.

The MPP represented a hope of overcoming this limitation of geographical scope, since it was announced as a mean of promoting access for all developing countries. That promise is not being fulfilled. Some countries that were not included in the licenses negotiated between Gilead and  Indian companies a few years ago were covered in the agreement negotiated with the MPP, but many countries are still excluded. We consider unacceptable the discrimination between countries and to let companies decide which populations can be benefited.

Thus, the MPP is not helping to prevent Latin American patients from having their treatment interrupted because of the high cost of drugs and to protect the sustainability of health programs. We believe that the MPP has the potential to make the public health needs take precedence over commercial requirements and thereby collaborate for overcoming the barriers to access to essential medicines, such as market segmentations.

At the political level, we recall that at the UNGASS 2011 Political Declaration on HIV, paragraph 71, C, countries commit to remove obstacles limiting the ability of low-income and middle-income countries to supply ARV treatment, and that the use of MPP was pointed as an alternative for this purpose.


Therefore, it is alarming that many countries in Latin America are excluded from the MPP License with Gilead. According to recent UNAIDS report, countries in this region have spent increasingly their scarce public resources to supply AIDS treatment. In addition, the current scenario of global retreat from international donors for projects on HIV / AIDS affects especially Latin America. The region has often been forgotten and is the only one from the global south that has not been cited in the recent UNGASS 2011 Political Declaration on HIV. In the context faced by our continent, where demand for the incorporation of new drugs protected by patents - as may be the case of cobicistat and elvitegravir - is large, the MPP could play a key role ensuring more affordable prices to these countries. However, this is not what happened in the first license signed with a pharmaceutical company.

In addition, the MPP was established by UNITAID as an entity to which companies, researchers and universities would license their patents on essential drugs and then any company interested in using the inventions could negotiate a license with the MPP, under predetermined conditions. That promise is not being fulfilled as well. The license announced on the July 12th established that only Indian companies can negotiate with the MPP. Other countries with capacity to produce generics were excluded, contrary to the initial proposal of encouraging multiple producers and lower prices through competition. 

We, civil society organizations of various countries excluded from the license negotiated between the MPP and Gilead express our displeasure with this agreement and call for non-discrimination principles defended by the MPP to be adopted in this negotiation and upcoming ones.

We expect much more from the "Medicines Patent Pool" and call this entity to defend the interests and needs of the populations of developing countries, always acting in accordance with the principles under which it was created. We demand that these principles be considered non-negotiable within the agreements negotiated with pharmaceutical companies. Finally, we hope that this agreement do not become the template for future negotiations, taking forward a practice contrary to the principles of the MPP and generating an unacceptable exclusion of Latin America and other regions.




Acción Ciudadana Contra el Sida - ACCSI - Venezuela

Acciones Voluntarias sobre Educación – AVE-  México 

Alianza LAC Global por el Acceso a Medicamentos 

ALUVIH/SUR  - Argentina

ASEPO (Asociación de Ayuda al Soro Positivo)

Asociación Animo y ALiento

Asociación Coordinadora de Sectores de Lucha Contra el Sida  - ACSLCS

Asociación Cristiana de Jóvenes – El Salvador

Asociación Gente Nueva - Guatemala

Asociación Nacional de Personas Positivas Vida Nueva - El Salvador.

Asociación para la Salud y la Ciudadania en América Latina - ASICAL

Asociación Amigos por Siempre Promoviendo tus Derechos- AAxS - Perú

Asociación Portadores de Vida- Formosa - Argentina

Associação Brasileira Interdisciplinar de Aids -ABIA - Brasil

Avellaneda - Argentina

Balance Promoción para el Desarrollo y Juventud - México

Coalición Ecuatoriana de personas que viven con VIH/Sida – Equador

Coalición Internacional de Activistas en Tratamientos

Colectivo Córdoba solidária - Argentina

Comité Salud 

Condomóvil – México

Conectas Direitos Humanos - Brasil

Corporación Kimirina - Equador

Derechohabientes Viviendo con VIH del IMSS (DVVIMSS)

EAM Guanabacoa AMISTAD

Foro de Ongs en la Lucha Contra el VIH – El Salvador

Fundación Arcoiris por el respeto a la diversidad sexual - México
Closet de Sor Juana -  México

Fundación Buenos Aires Sida - Argentina

Fundación Huellas - Equador

Fundación Huésped – Argentina

Fundación Manodiversa – Bolívia

Fundación Misión Salud - Colômbia

Fundación para Estudio e Investigación de la Mujer -FEIM 

GAPA/ SP - Brasil

Gente Buena del Sur - Argentina

Gestos – Brasil

Grupo de Resistência Asa Branca - GRAB - Brasil

Grupo Esperanza y Vida

Grupo Genesis Panamá + - Panamá

Grupo pela Vidda/RJ - Brasil

Grupo Pela Vidda/SP - Brasil

Instituto de Defesa do Consumidor - IDEC - Brasil

Instituto de Estudios de La Mujer "Norma Virginia Guirola de Herrera”– El Salvador

International AIDS Women Caucus -IAWC

Intilla Asociación Civil – Argentina

La Asociación por La Vida (ASOVIDA) - Venezuela

La Mesa de Organizaciones con trabajo en VIH/sida - Colômbia

La Red de Ongs y Obc con trabajo en VIH/Sida del Interior de Venezuela (REDIVIH)


Licencia Obligatoria - Colômbia

Lídice Lopez, Activista Independiente - Perú

LIGA Bonaerense de Diversidad sexual - Argentina

Liga Colombiana de Lucha Contra el Sida - Colômbia

Luz M. Umbasia Bernal, abogada

Movimiento Latinoamericano y del Caribe de Mujeres Positivas – Uruguay

Movimiento Latinoamericano y del Caribe de Mujeres Positivas (Regional)

Movimiento Mexicano de Ciudadanía Positiva - México

Mujer y Salud en Uruguay – MYSU – Uruguay

Mujeres en Positivo por Venezuela - Venezuela

Observatorio Centroamericano VIH

Observatório Latino

Projeto Esperança de São Miguel Paulista – PROJESP - Brasil

Red Argentina de Mujeres Viviendo con VIH-sida (RAMVIHS)- Argentina

Red Argentina de Personas Positivas (Redar Positiva) - Argentina

Red Bonaerense de Personas viviendo con VIH - Argentina 

Red de Personas con VIH/sida Mar del Plata

Red de PVVS de la Frontera Uruguay-Brasil.

Red de Salud de las Mujeres Latinoamericanas y del Caribe – RSMLAC

Red Latinoamericana de Personas con VIH - REDLA+

Red Mexicana de Personas que Viven con VIH/SIDA - México

Red Nacional de Jóvenes y Adolescentes para la Salud Sexual y Reproductiva – Argentina

Red Peruana de Mujeres Viviendo con VIH – Perú

Red Venezolana de Gente Positiva - Venezuela

Red Venezolana de Mujeres Positivas – RVM+ - Venezuela

RNP+ São Luís - Brasil

Senderos Asociación Mutual de Cali - Colômbia

Sra Silvia Gigena 

TRAVESIA  - Argentina

Vivir. Participación, Incidencia y Transparencia – México





Veriano Terto Jr. - verterto at abiaids.org.br / +55 21 2223-1040

Coordenador Geral 

Associação Brasileira Interdisciplinar de Aids - ABIA


Felipe de Carvalho – felipe at abiaids.org.br / +55 21 2223-1040

Assessor de imprensa 

Grupo de Trabalho sobre Propriedade Intelectual (GTPI/Rebrip)


Pedro Villardi – pedro at abiaids.org.br / +55 21 2223-1040

Assessor de Projetos

Grupo de Trabalho sobre Propriedade Intelectual (GTPI/Rebrip)


Sérgio Costa Souza - sergio.souza.costa at gmail.com 

Consultor independente

Grupo de Trabalho sobre Propriedade Intelectual (GTPI/Rebrip)


More information about the Ip-health mailing list